Impact of comorbidities constituting the HCT-CI score on the outcome of patients undergoing allogeneic HCT for AML.

TL;DR: A comprehensive review of the literature and critically examined recent available data, mostly using the PubMed and Medline search engines for original articles published over the last decade is performed in this paper, where the first-in-class complement inhibitor eculizumab has significantly improved outcomes in both the pediatric and adult population.

TL;DR: High blood pressure within 28 days after allo-HCT was associated with inferior survival outcomes, especially in patients younger than 50 years, and baseline asBP before commencement of the conditioning regimen and elevation of asBP were bothassociated with inferior NRM.

TL;DR: A state-of-the-art review aiming to summarize current knowledge on endothelial dysfunction, subclinical target organ damage and CV risk prediction in HCT survivors is conducted.

TL;DR: Evaluated the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF), finding that pulmonary disease and renal dysfunction were most adversely associated with OS.

TL;DR: High blood pressure within 28 days after allo-HCT was associated with inferior survival outcomes, especially in patients younger than 50 years, and baseline asBP before commencement of the conditioning regimen and elevation of asBP were bothassociated with inferior NRM.

TL;DR: A state-of-the-art review aiming to summarize current knowledge on endothelial dysfunction, subclinical target organ damage and CV risk prediction in HCT survivors is conducted.